Michael A. Patane - 01 Dec 2023 Form 4 Insider Report for TFF Pharmaceuticals, Inc.

Reporting relationship: Director
Issuer ticker: N/A
Reported as of: 01 Dec 2023
Net transaction value: $0
SEC form: 4
Accepted by SEC: 04 Dec 2023, 17:28:13 UTC
Next SEC filing: 22 Apr 2024
Source filing: View source filing
Reporting owner signature: /s/ Michael A Patane

Key filing fact

Michael A. Patane filed Form 4 for TFF Pharmaceuticals, Inc. on 04 Dec 2023.

Key facts

This page summarizes Michael A. Patane's Form 4 filing for TFF Pharmaceuticals, Inc..
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 04 Dec 2023, 17:28.

Change

No earlier filing in this sequence is available for direct comparison.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

TFFP transaction Derivative

Stock Options (Right to Buy)

Award

Transaction value: $0
Shares: +132,442
Change %
Price: $0.000000
Shares after: 132,442
Date: 01 Dec 2023
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 132,442
Exercise price: $0.3600
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The options vest and first become exercisable in 36 equal monthly installments, with the first installment vesting on December 1, 2024 and the remaining installments on the 1st of the month for the next 35 months.